NCT00450827已完成1 期
Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8 and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroblastoma by blocking blood flow to the tumor. Giving iodine I 131 monoclonal antibody 3F8 together with bevacizumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 monoclonal antibody 3F8 when given together with bevacizumab in treating patients with relapsed or refractory neuroblastoma.
详细描述
OBJECTIVES:
Primary
- Determine the toxicity of iodine I 131 monoclonal antibody 3F8 (^131I-3F8) and bevacizumab in patients with relapsed or refractory neuroblastoma.
- Determine the hematopoietic recovery after autologous stem cell rescue in patients treated with this regimen.
Secondary
- Determine the clinical response rates in patients treated with this regimen.
- Assess whole body dosimetry for ^131I-3F8.
- Assess tumor targeting of ^131I-3F8 before and after bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines.
- •Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy.
- •Patients must have evaluable (microscopic marrow metastasis, MIBG or PET scans) or measurable (CT, MRI) disease.
- •Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy or radioimmunotherapy.
- •Age >1 year and able to cooperate with radiation safety restrictions during therapy period.
- •Stem cells: Patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. The minimum dose for hematopoietic stem cells is 2 X106 CD34+ cells/kg.
- •Minimum life expectancy of four weeks.
- •Signed informed consent indicating awareness of the investigational nature of this program.
排除标准
- •Severe major organ toxicity. Renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less (per NCI CTC version 3 criteria). Specifically, serum creatinine should be ≤3 x upper limit of normal (ULN), serum AST and ALT ≤5 x ULN, serum bilirubin ≤ 3 x ULN, LV shortening fraction should be ≥15%.
- •Patients with myelosuppression are not excluded if ANC ≥ 500/uL. Platelet count should be > 50,000/ul and hemoglobin should be > 8gm/dl. Patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levels.
- •Patients with documented chronic non-healing wound, ulcer or bone fracture
- •Surgical procedures.
- •Patients who have undergone major surgery <28 days prior to beginning therapy with bevacizumab are excluded.
- •Patients must be least 24 hours from having after surgical procedures such as placement of central catheter.
- •Patients <7days from minor surgeries (e.g. fine needle or core biopsies) and/or the unhealed wounds from these procedures are excluded.
- •Patients will be excluded if major surgery (e.g. abdominal or thoracic surgery for resection of tumor) is anticipated during the course of the study.
- •Known bleeding diathesis or coagulopathy. Patients on anti-coagulants (except for heparin flushes for centra venous catheter maintenance) are excluded.
- •Thrombosis: patients must not have had a deep venous or arterial thrombosis (non-central venous catheter related) within the last three months prior to study entry. Patients with cerebrovascular accident or transient ischemic attack within 6 months of therapy are excluded. Patients with history of peripheral vascular disease, myocardial infarction or unstable angina are excluded.
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry.
- •Pulmonary or CNS metastases: pre-therapy CT or MRI of head and chest must be carried out.
- •Proteinuria: Urine protein: creatinine ratio ≥ 1.0
- •Uncontrolled hypertension.
- •HAMA >1000 ELISA units/ml.
- •History of allergy to mouse proteins, Chinese hamster ovary cells products or other recombinant human antibodies
- •Active serious infections not controlled by antibiotics.
- •Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.
- •Inability or unwillingness to comply with radiation safety procedures or protocol requirements.
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerBrain and Central Nervous System TumorsIntraocular MelanomaMelanoma (Skin)Metastatic CancerSmall Intestine CancerLung CancerOvarian CancerRetinoblastomaSarcomaNeuroblastomaNCT00445965Memorial Sloan Kettering Cancer Center78
已完成
1 期
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00058292Northwestern University44
终止
2 期
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRefractory Anemia With Ringed SideroblastsChronic Myelomonocytic LeukemiaRefractory Cytopenia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesNCT00119366Fred Hutchinson Cancer Center18
已完成
1 期
Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's LymphomaLymphomaNCT00574509University of Nebraska34
已完成
1 期
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed NeuroblastomaNeuroblastomaNCT00450307Memorial Sloan Kettering Cancer Center32